Literature DB >> 21710693

Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients.

Chiara Grisanzio1, Apryle Seeley, Michelle Chang, Michael Collins, Arianna Di Napoli, Su-Chun Cheng, Andrew Percy, Rameen Beroukhim, Sabina Signoretti.   

Abstract

Renal cell carcinoma (RCC) is an aggressive malignancy with limited responsiveness to existing treatments. In vivo models of human cancer, including RCC, are critical for developing more effective therapies. Unfortunately, current RCC models do not accurately represent relevant properties of the human disease. The goal of this study was to develop clinically relevant animal models of RCC for preclinical investigations. We transplanted intact human tumour tissue fragments orthotopically in immunodeficient mice. The xenografts were validated by comparing the morphological, phenotypic and genetic characteristics of the kidney tumour tissues before and after implantation. Twenty kidney tumours were transplanted into mice. Successful tumour growth was detected in 19 cases (95%). The histopathological and immunophenotypic features of the xenografts and those of the original tumours largely overlapped in all cases. Evaluation of genetic alterations in a subset of 10 cases demonstrated that the grafts largely retained the genetic features of the pre-implantation RCC tissues. Indeed, primary tumours and corresponding grafts displayed identical VHL mutations. Moreover, an identical pattern of DNA copy amplification or loss was observed in 6/10 cases (60%). In summary, orthotopic engrafting of RCC tissue fragments can be successfully used to generate animal models that closely resemble RCC in patients. These models will be invaluable for in vivo preclinical drug testing and for deeper understanding of kidney carcinogenesis. The raw data of the SNP array analysis has been submitted to the GEO database (Accession No. GSE29062).
Copyright © 2011 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21710693      PMCID: PMC3793840          DOI: 10.1002/path.2929

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  59 in total

Review 1.  Renal-cell carcinoma.

Authors:  R J Motzer; N H Bander; D M Nanus
Journal:  N Engl J Med       Date:  1996-09-19       Impact factor: 91.245

2.  Evaluation of the clonal relationship between primary and metastatic renal cell carcinoma by comparative genomic hybridization.

Authors:  H Bissig; J Richter; R Desper; V Meier; P Schraml; A A Schäffer; G Sauter; M J Mihatsch; H Moch
Journal:  Am J Pathol       Date:  1999-07       Impact factor: 4.307

3.  Orthotopic implantation of colon carcinoma cells provides an experimental model in the rat that replicates the regional spreading pattern of human colorectal cancer.

Authors:  D García-Olmo; M García-Rivas; D C García-Olmo; M Atiénzar
Journal:  Cancer Lett       Date:  1998-10-23       Impact factor: 8.679

4.  Development of a high metastatic orthotopic model of human renal cell carcinoma in nude mice: benefits of fragment implantation compared to cell-suspension injection.

Authors:  Z An; P Jiang; X Wang; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  1999-05       Impact factor: 5.150

5.  Prognostic value of Ki-67 expression in renal cell carcinomas.

Authors:  S Aaltomaa; P Lipponen; M Ala-Opas; M Eskelinen; K Syrjänen
Journal:  Eur Urol       Date:  1997       Impact factor: 20.096

6.  Comprehensive allelotyping of human renal cell carcinomas using microsatellite DNA probes.

Authors:  C A Thrash-Bingham; R E Greenberg; S Howard; A Bruzel; M Bremer; A Goll; H Salazar; J J Freed; K D Tartof
Journal:  Proc Natl Acad Sci U S A       Date:  1995-03-28       Impact factor: 11.205

7.  Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation.

Authors:  F Jiang; H Moch; J Richter; C Egenter; T Gasser; L Bubendorf; R Gschwind; G Sauter; M J Mihatsch
Journal:  J Pathol       Date:  1998-08       Impact factor: 7.996

8.  Intratumoral heterogeneity of von Hippel-Lindau gene deletions in renal cell carcinoma detected by fluorescence in situ hybridization.

Authors:  H Moch; P Schraml; L Bubendorf; J Richter; T C Gasser; M J Mihatsch; G Sauter
Journal:  Cancer Res       Date:  1998-06-01       Impact factor: 12.701

9.  Genomic alterations and instabilities in renal cell carcinomas and their relationship to tumor pathology.

Authors:  C A Thrash-Bingham; H Salazar; J J Freed; R E Greenberg; K D Tartof
Journal:  Cancer Res       Date:  1995-12-15       Impact factor: 12.701

View more
  21 in total

Review 1.  Patient-derived xenografts as in vivo models for research in urological malignancies.

Authors:  Takahiro Inoue; Naoki Terada; Takashi Kobayashi; Osamu Ogawa
Journal:  Nat Rev Urol       Date:  2017-02-21       Impact factor: 14.432

Review 2.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

3.  Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.

Authors:  Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2014-04-09       Impact factor: 5.150

4.  A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma.

Authors:  Sharanya Sivanand; Samuel Peña-Llopis; Hong Zhao; Blanka Kucejova; Patrick Spence; Andrea Pavia-Jimenez; Toshinari Yamasaki; David J McBride; Jessica Gillen; Nicholas C Wolff; Lorraine Morlock; Yair Lotan; Ganesh V Raj; Arthur Sagalowsky; Vitaly Margulis; Jeffrey A Cadeddu; Mark T Ross; David R Bentley; Wareef Kabbani; Xian-Jin Xie; Payal Kapur; Noelle S Williams; James Brugarolas
Journal:  Sci Transl Med       Date:  2012-06-06       Impact factor: 17.956

Review 5.  Choosing The Right Animal Model for Renal Cancer Research.

Authors:  Paweł Sobczuk; Anna Brodziak; Mohammed Imran Khan; Stuti Chhabra; Michał Fiedorowicz; Marlena Wełniak-Kamińska; Kamil Synoradzki; Ewa Bartnik; Agnieszka Cudnoch-Jędrzejewska; Anna M Czarnecka
Journal:  Transl Oncol       Date:  2020-02-22       Impact factor: 4.243

6.  Stability of preclinical models of aggressive renal cell carcinomas.

Authors:  Mariana Varna; Guilhem Bousquet; Irmine Ferreira; Marie Goulard; Morad El-Bouchtaoui; Pierre Mongiat Artus; Jérome Verine; Eric de Kerviler; Lucie Hernandez; Christophe Leboeuf; Bernard Escudier; Luc Legrès; Niclas Setterblad; Hany Soliman; Jean-Paul Feugeas; Anne Janin; Philippe Bertheau
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

7.  Establishing a human renal cell carcinoma tumorgraft platform for preclinical drug testing.

Authors:  Andrea Pavía-Jiménez; Vanina Toffessi Tcheuyap; James Brugarolas
Journal:  Nat Protoc       Date:  2014-07-10       Impact factor: 13.491

8.  Tissue slice grafts of human renal cell carcinoma: an authentic preclinical model with high engraftment rate and metastatic potential.

Authors:  Alan E Thong; Hongjuan Zhao; Alexandre Ingels; Maija P Valta; Rosalie Nolley; Jennifer Santos; Sarah R Young; Donna M Peehl
Journal:  Urol Oncol       Date:  2013-08-02       Impact factor: 3.498

9.  Origin of the vasculature supporting growth of primary patient tumor xenografts.

Authors:  Bonnie L Hylander; Natalie Punt; Haikuo Tang; Joanna Hillman; Mary Vaughan; Wiam Bshara; Rose Pitoniak; Elizabeth A Repasky
Journal:  J Transl Med       Date:  2013-05-03       Impact factor: 5.531

10.  Characterization of the Tumor-Microenvironment in Patient-Derived Cervix Xenografts (OCICx).

Authors:  Naz Chaudary; Melania Pintilie; Joerg Schwock; Neesha Dhani; Blaise Clarke; Michael Milosevic; Anthony Fyles; Richard P Hill
Journal:  Cancers (Basel)       Date:  2012-08-29       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.